Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Qiagen ( (QGEN) ) just unveiled an update.
On November 4, 2025, QIAGEN announced its third-quarter financial results, showing a 6% increase in net sales compared to the previous year, and raised its full-year adjusted EPS target to $2.38. The company also revealed plans to acquire Parse Biosciences, expanding its Sample technologies portfolio into the single-cell market, and announced a $500 million synthetic share repurchase to enhance shareholder value. Additionally, CEO Thierry Bernard will step down after a successor is appointed, marking a leadership transition.
The most recent analyst rating on (QGEN) stock is a Hold with a $48.00 price target. To see the full list of analyst forecasts on Qiagen stock, see the QGEN Stock Forecast page.
Spark’s Take on QGEN Stock
According to Spark, TipRanks’ AI Analyst, QGEN is a Neutral.
Qiagen’s overall stock score is driven by strong earnings call performance and stable financials. However, technical analysis indicates bearish momentum, and valuation metrics suggest potential overvaluation. The company’s strategic initiatives and growth plans provide a positive outlook, but challenges in profitability growth and cash flow conversion remain.
To see Spark’s full report on QGEN stock, click here.
More about Qiagen
QIAGEN N.V. operates in the biotechnology industry, focusing on providing sample and assay technologies for molecular diagnostics, applied testing, academic and pharmaceutical research. The company is known for its products such as QIAstat-Dx and QuantiFERON, and it aims to expand its market presence in the single-cell market through strategic acquisitions.
Average Trading Volume: 1,236,450
Technical Sentiment Signal: Sell
Current Market Cap: $9.58B
For a thorough assessment of QGEN stock, go to TipRanks’ Stock Analysis page.